--- title: "Beam Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.74 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285537088.md" datetime: "2026-05-07T11:11:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285537088.md) - [en](https://longbridge.com/en/news/285537088.md) - [zh-HK](https://longbridge.com/zh-HK/news/285537088.md) --- # Beam Therapeutics | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 31.74 M Revenue: As of FY2026 Q1, the actual value is USD 31.74 M, beating the estimate of USD 12.22 M. EPS: As of FY2026 Q1, the actual value is USD -0.91, beating the estimate of USD -1.0166. #### Financial Performance Beam Therapeutics Inc. reported a net loss of - $94,318 thousand for the first quarter of 2026, which improved from a net loss of - $108,330 thousand for the first quarter of 2025. License and collaboration revenue significantly increased to $31,738 thousand for the first quarter of 2026, up from $7,470 thousand in the prior year period. Loss from operations was - $107,215 thousand for the first quarter of 2026, compared to - $119,286 thousand for the first quarter of 2025. Total operating expenses were $138,953 thousand for the first quarter of 2026, an increase from $126,756 thousand for the first quarter of 2025. Weighted-average common shares outstanding were 103,262,001 for the first quarter of 2026, an increase from 87,975,311 for the first quarter of 2025. #### Operating Costs Research & Development (R&D) expenses for the first quarter of 2026 were $104,524 thousand, an increase from $98,816 thousand for the first quarter of 2025. General & Administrative (G&A) expenses also rose to $34,429 thousand for the first quarter of 2026, compared to $27,940 thousand for the first quarter of 2025. #### Cash Position and Balance Sheet As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $1,211,652 thousand, a slight decrease from $1,245,210 thousand as of December 31, 2025. Total assets were $1,480,798 thousand as of March 31, 2026, compared to $1,481,177 thousand as of December 31, 2025. Total liabilities increased to $316,360 thousand as of March 31, 2026, from $242,819 thousand as of December 31, 2025. Total stockholders’ equity was $1,164,438 thousand as of March 31, 2026, down from $1,238,358 thousand as of December 31, 2025. #### Unique Operational Metrics (Pipeline Updates) Beam Therapeutics Inc. reported strong single-dose safety and efficacy for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD), with the 60 mg dose selected as optimal, and plans to initiate a global pivotal cohort for BEAM-302 in the second half of 2026. Data from the Phase 1⁄2 BEACON clinical trial of Risto-cel in Sickle Cell Disease were published, with a U.S. Biologics License Application (BLA) submission for Risto-cel expected as early as year-end 2026. An Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU) and initial clinical data from BEAM-301 in Glycogen Storage Disease type 1a (GSDIa) are anticipated in 2026, while the Phase 1 healthy volunteer clinical trial of BEAM-103 is expected to complete dosing in the first half of 2026. #### Outlook / Guidance Beam Therapeutics Inc. anticipates that its cash, cash equivalents, and marketable securities as of March 31, 2026, including $100 million already received and an anticipated additional $100 million from a financing agreement, will fund its operating expenses and capital expenditure requirements into mid-2029. This cash runway is expected to support the anticipated launch of Risto-cel in Sickle Cell Disease, the execution of the BEAM-302 pivotal development plan in AATD, and the achievement of clinical proof of concept for BEAM-304 in PKU. ### Related Stocks - [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md) ## Related News & Research - [A Look At Beam Therapeutics (BEAM) Valuation As New BEACON Trial Data And Partnerships Draw Attention](https://longbridge.com/en/news/286662919.md) - [Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances](https://longbridge.com/en/news/287103341.md) - [Financial year ending 31 March 2026 reports final results.](https://longbridge.com/en/news/287166907.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Gentoo Media publishes Q1 2026 interim report](https://longbridge.com/en/news/287169902.md)